Publicaciones científicas

/cun/investigacion/publicaciones-cientificas/areaMain/02
  • A novel concept to include uncertainties in the evaluation of stereotactic body radiation therapy after 4D dose accumulation using deformable image registration

    Azcona JD (1), Huesa-Berral C (1,2), Moreno-Jiménez M (3), Barbés B (1), Aristu JJ (3), Burguete J (2.)

    (1) Service of Radiation Physics and Radiation Protection, Clínica Universidad de Navarra, Avda. Pío XII, 36. 31008, Pamplona, Navarra, Spain.
    (2) Department of Physics and Applied Mathematics, School of Sciences, Universidad de Navarra. C/ Irunlarrea, 1. 31008, Pamplona, Navarra, Spain.
    (3) Service of Radiation Oncology, Clínica Universidad de Navarra, Avda. Pío XII, 36. 31008, Pamplona, Navarra, Spain.

    Medical Physics 11 de AGOSTO de 2019

  • The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Martínez-Vélez N (1,2,3), Garcia-Moure M (1,2,3), Marigil M (1,2,3), González-Huarriz M (1,2,3), Puigdelloses M (1,2,4), Gallego Pérez-Larraya J (1,2,4), Zalacaín M (1,2,3), Marrodán L (1,2,3), Varela-Guruceaga M (1,2,3), Laspidea V (1,2,3), Aristu JJ (1,5), Ramos LI (1,5), Tejada-Solís S (1,6), Díez-Valle R (1,6), Jones C (7,8), Mackay A (7,8), Martínez-Climent JA (1,9), García-Barchino MJ (1,9), Raabe E (10,11), Monje M (12), Becher OJ (13), Junier MP (14), El-Habr EA (14), Chneiweiss H (14), Aldave G (15), Jiang H (16), Fueyo J (16,17), Patiño-García A (1,2,3), Gomez-Manzano C (18), Alonso MM (19,20,21).

    (1) Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (2) Program of Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Navarra, Pamplona, Spain.
    (3) Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.
    (4) Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain.
    (5) Department of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (6) Department of Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain.
    (7) Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, Surrey, SM2 5NG, UK.
    (8) Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, Surrey, SM2 5NG, UK.
    (9) Division of Hematopoietic Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, CIBERONC, Pamplona, Pamplona, Navarra, Spain.
    (10) Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
    (11) Division of Pediatric Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
    (12) Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA.
    (13) Department of Pediatrics, Northwestern University and Division of Pediatric Hematology-Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA.
    (14) CNRS UMR8246, Inserm U1130, Neuroscience Paris Seine - IBPS, Sorbonne Universities, Paris, France.
    (15) Division of Pediatric Neurosurgery, Department of Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
    (16) Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (17) Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (18) Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (19) Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (20) Program of Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Navarra, Pamplona, Spain.
    (21) Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.

    Nature Communications 28 de MAYO de 2019

  • Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models

    Martinez-Velez N (1,2,3), Marigil M (1,2,3,4), García-Moure M (1,2,3), Gonzalez-Huarriz M (1,2,3), Aristu JJ (1,5), Ramos-García LI (5), Tejada S (1,2,6), Díez-Valle R (1,2,6), Patiño-García A (1,2,3), Becher OJ (7), Gomez-Manzano C (8,9), Fueyo J (8,10), Alonso MM (11,12,13).

    (1) The Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (2) Program in Solid Tumors, Foundation for the Applied Medical Research, Pamplona, Navarra, Spain.
    (3) Department of Pediatrics, Clínica Universidad de Navarra, University of Navarra, CIMA Building, Avd. Pio XII, 55, Pamplona, Spain.
    (4) Division of Neurosurgery, Lariboisière University Hospital, 2 Rue Ambroise Paré, 75475, Paris, cedex 10, France.
    (5) Department of Radiation Oncology, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (6) Department of Neurosurgery, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (7) Department of Pediatrics, Northwestern University and Division of Pediatric Hematology-Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA.
    (8) Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (9) Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (10) Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (11) The Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (12) Program in Solid Tumors, Foundation for the Applied Medical Research, Pamplona, Navarra, Spain.
    (13) Department of Pediatrics, Clínica Universidad de Navarra, University of Navarra, CIMA Building, Avd. Pio XII, 55, Pamplona, Spain.

    Acta Neuropathologica Communications 29 de ABRIL de 2019

  • Rescuing Spanish Radiation Therapy: The Role of Leadership and Opportunity

    Lara PC (1), Rodríguez A (2), Ferrer C (3), Aristu JJ (4), Prada PJ (5), Muñoz J (6), Arenas M (7), Perez-Montero H (8)

    (1) Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas Gran Canaria, Spain.
    (2) Radiation Oncology Department, Hospital Ruber Internacional, Madrid, Spain.
    (3) Radiation Oncology Department, Complejo Hospitalario de Castellón, Castellón, Spain.
    (4) Radiation Oncology Department, Clínica Universitaria de Navarra, Pamplona, Spain.
    (5) Radiation Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
    (6) Radiation Oncology Department, Hospital Universitario Infanta Cristina, Badajoz, Spain.
    (7) Radiation Oncology Department, Hospital Universitario Sant Joan, Reus, Spain.
    (8) Radiation Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.

    International Journal Radiation Oncology, Biology, Physics 01 de FEBRERO de 2018

  • A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients

    Inogés S (1,2), Tejada S (3), de Cerio AL (4,5), Pérez-Larraya JG (6), Espinós J (7), Idoate MA (8), Domínguez PD (9), de Eulate RG (9), Aristu J (10), Bendandi M (11,12), Pastor F (13), Alonso M (14), Andreu E (5), Cardoso FP (4,15), Valle RD (16). (1) Cell Therapy Area, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (2) Immunology and Immunotherapy Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (3) Neurosurgery Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (4) Cell Therapy Area, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (5) Immunology and Immunotherapy Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (6) Neurology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (7) Oncology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (8) Pathology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (9) Radiology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (10) Radiation Oncology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (11) Section on Hematology/Oncology, Department of Internal Medicine, Comprehensive Cancer Center, Wake Forest University Baptist Healthcare Center, Winston-Salem, NC, USA.
    (12) Section of Hematology/Oncology, Department of Internal Medicine, W.G Hefner VA Medical Center, Salisbury/Charlotte, NC, USA.
    (13) Program of Molecular Therapies, Aptamer Unit, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Avenida Pio XII 55, 31008, Pamplona, Navarra, Spain.
    (14) Program in Solid Tumors and Biomarkers, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Avenida Pio XII 55, 31008, Pamplona, Navarra, Spain.
    (15) Haematology and Haemotherapy Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (16) Neurosurgery Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain

    Journal of Transational Medicine 12 de MAYO de 2017

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra